Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor ModulatorGlobeNewsWire • 05/23/23
Societal CDMO to Participate in RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/09/23
Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexin™GlobeNewsWire • 05/08/23
Societal CDMO to Report Financial Results for First Quarter 2023 on May 10, 2023GlobeNewsWire • 05/03/23
Societal CDMO Signs Multiple Project Expansion Agreements With Existing CustomersGlobeNewsWire • 04/12/23
Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development of LP352GlobeNewsWire • 04/05/23
Societal CDMO Announces U.S. FDA Approval for Manufacturing of Commercial Tablet at Gainesville, Georgia SiteGlobeNewsWire • 03/20/23
Societal CDMO to Report Financial Results for Fourth Quarter and Year-End 2022 on March 1, 2023GlobeNewsWire • 02/22/23
Societal CDMO Highlights Growth of Existing Customer Business Through Signing of More Than $6 Million in Work Orders During Fourth Quarter of 2022GlobeNewsWire • 02/01/23
Societal CDMO Completes Strategic Recast of Capital Structure Highlighted by Reduction and Refinancing of Outstanding DebtGlobeNewsWire • 12/16/22
Societal CDMO Announces Proposed Concurrent Public Offerings of Common Stock and Preferred StockGlobeNewsWire • 12/12/22
Societal CDMO Advances Multi-Step Strategy to Recast Capital Structure and Strengthen Balance SheetGlobeNewsWire • 12/12/22
Societal CDMO to Report Financial Results for Third Quarter 2022 on November 9, 2022GlobeNewsWire • 11/02/22
Societal CDMO Announces Signing of More Than $9 Million Sales and Purchase Agreement With David Weekley Homes for Excess Lakefront LandGlobeNewsWire • 08/16/22
Societal CDMO, Inc.'s (SCTL) CEO David Enloe on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22